Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer

REFERENCES

• Beatson G. On the treatment of inoperable cases of carcinoma of the mammary: sugges tions for a new method of treatment, with illustrative cases. Lancet 1896; 104–107
   Google Scholar
• Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980–991
   PubMed Web of Science ®Google Scholar
• Bergh J., Holmquist M. Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 2001; 30: 103–108
   PubMedGoogle Scholar
• Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–752
   PubMed Web of Science ®Google Scholar
• Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531–537
   PubMed Web of Science ®Google Scholar
• Simon R., Radmacher M.D., Dobbin K. Design of studies using DNA microarrays. Genet Epidemiol 2002; 23: 21–36
   PubMed Web of Science ®Google Scholar
• Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–10874
   PubMed Web of Science ®Google Scholar
• Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418–8423
   PubMed Web of Science ®Google Scholar
• Yu K., Lee CH., Tan P.H., et al. Conservation of breast cancer molecular subtypes and tran-scriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004; 10: 5508–5517
   PubMed Web of Science ®Google Scholar
• Van Laere S.J., Van den Eynden G.G., Van der Auwera I. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006; 95(3)243–255
   PubMed Web of Science ®Google Scholar
• Weigelt B., Hu Z., He X., et al. Molecular portraits and 70-gene prognosis signature are pre served throughout the metastatic process of breast cancer. Cancer Res 2005; 65: 9155–9158
   PubMed Web of Science ®Google Scholar
• Abd El-Rehim D.M., Ball G., Finder S.E., et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologi cally distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340–350
   PubMed Web of Science ®Google Scholar
• Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 2006; 7: 96
   PubMed Web of Science ®Google Scholar
• Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367–5374
   PubMed Web of Science ®Google Scholar
• King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643–646
   PubMed Web of Science ®Google Scholar
• Chappuis P.O., Nethercot V., Foulkes W.D. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000; 18: 287–295
   PubMed Web of Science ®Google Scholar
• Foulkes W.D., Stefansson I.M., Chappuis P.O., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482–1485
   PubMed Web of Science ®Google Scholar
• Olopade O.I., Grushko T. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 2028–2029
   PubMed Web of Science ®Google Scholar
• van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530–536
   PubMed Web of Science ®Google Scholar
• Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 2006; 295: 2492–2502
   PubMed Web of Science ®Google Scholar
• Chlebowski R.T., Chen Z., Anderson G.L., et al. Ethnicity and breast cancer: factors influen cing differences in incidence and outcome. J Natl Cancer Inst 2005; 97: 439–448
   PubMed Web of Science ®Google Scholar
• Gapstur S.M., Dupuis J., Gann P., et al. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer 1996; 77: 1465–1471
   Google Scholar
• Colditz G.A., Rosner B.A., Chen W.Y., et al. Risk factors for breast cancer according to estro gen and progesterone receptor status. J Natl Cancer Inst 2004; 96: 218–228
   PubMed Web of Science ®Google Scholar
• Chen W.Y., Hankinson S.E., Schnitt S.J., et al. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004; 101: 1490–1500
   PubMed Web of Science ®Google Scholar
• Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998; 90: 1371–1388
   PubMed Web of Science ®Google Scholar
• Suzuki R., Ye W., Rylander-Rudqvist T., et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst 2005; 97: 1601–1608
   PubMed Web of Science ®Google Scholar
• Fung T.T., Hu F.B., McCullough M.L., et al. Diet quality is associated with the risk of estrogen receptor-negative breast cancer in postmenopausal women. J Nutr 2006; 136: 466–472
   PubMed Web of Science ®Google Scholar
• Marshall S.F., Bernstein L., Anton-Culver H., et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005; 97: 805–812
   PubMed Web of Science ®Google Scholar
• Zhang S.M., Hankinson S.E., Hunter D.J., et al. Folate intake and risk of breast cancer characterized by hormone receptor status. Cancer Epidemiol Biomarkers Prev 2005; 14: 2004–2008
   PubMed Web of Science ®Google Scholar
• Faneyte I.F., Peterse J.L., Van Tinteren H., et al. Predicting early failure after adjuvant chemo therapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004; 10: 4457–4463
   PubMed Web of Science ®Google Scholar
• Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393–10398
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinilla S.M., Sarrio D., Honrado E., et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006; 12: 1533–1539
   PubMed Web of Science ®Google Scholar
• Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518–524
   PubMed Web of Science ®Google Scholar
• van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999–2009
   PubMed Web of Science ®Google Scholar
• Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24: 1665–1671
   PubMed Web of Science ®Google Scholar
• Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817–2826
   PubMed Web of Science ®Google Scholar
• Chang H.Y., Nuyten D.S., Sneddon J.B., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738–3743
   PubMed Web of Science ®Google Scholar
• Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607–616
   PubMed Web of Science ®Google Scholar
• Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355(6)560–569
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormo nal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717
   Google Scholar
• Colleoni M., Minchella I., Mazzarol G., et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000; 11: 1057–1059
   PubMed Web of Science ®Google Scholar
• Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037–1044
   PubMed Web of Science ®Google Scholar
• Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J Am Med Assoc 2006; 295: 1658–1667
   PubMed Web of Science ®Google Scholar
• Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond dif ferently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678–5685
   PubMed Web of Science ®Google Scholar
• Carey L.A., Dees E.C., Sawyer L.R., et al. The triple negative paradox: primary tumor chemosensitivity of the basal-like breast cancer (BBC) phenotype. San Antonio Breast Cancer Symposium 2004; 1023a
   Google Scholar
• Troester M.A., Hoadley K.A., Sorlie T., et al. Cell-type-specific responses to chemotherapeu-tics in breast cancer. Cancer Res 2004; 64: 4218–4226
   PubMed Web of Science ®Google Scholar
• Burris H.A., III, Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carci nomas. J Clin Oncol 2005; 23: 5305–5313
   PubMed Web of Science ®Google Scholar
• Konecny G.E., Pegram M.D., Venkatesan N., et al. Activity of the dual kinase inhibitor lapa tinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630–1639
   PubMed Web of Science ®Google Scholar
• Kennedy R.D., Quinn J.E., Mullan P.B., et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659–1668
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E., Ginestier C., Monville F., et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25: 2273–2284
   PubMed Web of Science ®Google Scholar
• Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264–271
   PubMed Web of Science ®Google Scholar
• Lev D.C., Kim L.S., Melnikova V., et al. Dual blockade of EGFR and ERK1/2 phosphory-lation potentiates growth inhibition of breast cancer cells. Br J Cancer 2004; 91: 795–802
   PubMed Web of Science ®Google Scholar
• Simon R., Panussis S., Maurer R., et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004; 10: 178–183
   PubMed Web of Science ®Google Scholar
• Modi S., Seidman A.D., Dickler M., et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005; 90: 157–163
   PubMed Web of Science ®Google Scholar
• Reis-Filho J.S., Westbury C., Pierga J.Y. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 2006; 59: 225–231
   PubMed Web of Science ®Google Scholar
• Reid J.F., Lusa L., De Cecco L., et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 2005; 97: 927–930
   PubMed Web of Science ®Google Scholar
• Simon R., Radmacher M.D., Dobbin K., et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95: 14–18
   PubMed Web of Science ®Google Scholar